Zurich Cantonal Bank
RAPT

Zurich Cantonal Bank’s RAPT Therapeutics RAPT Stock Holding History

Zurich Cantonal Bank’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16
Closed -$198 – 2675
2024
Q4 		$198 Sell
16
-73
-82% -$927 ﹤0.01% 2639
2024
Q3 		$1.43K Sell
89
-2
-2% -$40 ﹤0.01% 2641
2024
Q2 		$2.21K Sell
91
-492
-84% -$22.7K ﹤0.01% 2630
2024
Q1 		$41.9K Buy
583
+93
+19% +$12.9K ﹤0.01% 2580
2023
Q4 		$97.4K Sell
490
-145
-23% -$17.9K ﹤0.01% 2457
2023
Q3 		$84.5K Hold
635
– – ﹤0.01% 2428
2023
Q2 		$95.1K Hold
635
– – ﹤0.01% 2375
2023
Q1 		$93.3K Buy
635
+554
+684% +$112K ﹤0.01% 2321
2022
Q4 		$12.8K Sell
81
-16
-16% -$2.56K ﹤0.01% 2792
2022
Q3 		$19K Hold
97
– – ﹤0.01% 2809
2022
Q2 		$14K Sell
97
-10
-9% -$1.33K ﹤0.01% 2832
2022
Q1 		$19K Buy
+107
New +$20.2K ﹤0.01% 2670

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Zurich Cantonal Bank's RAPT Position: Q1 2025 in Review

Zurich Cantonal Bank sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 16 shares — an estimated $198 sold.

Zurich Cantonal Bank first reported a position in RAPT in Q1 2022 and held it in 12 quarters. The position peaked at $97.4K in Q4 2023. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Zurich Cantonal Bank reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 16 RAPT Therapeutics shares in Q1 2025, an estimated $198.
  • Zurich Cantonal Bank first reported a position in RAPT Therapeutics in Q1 2022 and held it in 12 quarters.
  • Zurich Cantonal Bank's RAPT Therapeutics position peaked at $97.4K in Q4 2023.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Zurich Cantonal Bank's 13F filing for Q1 2025, filed 7 May 2025.